US stock market anomalies | Chinese pharmaceutical stocks rise, Renaissance Pharmaceuticals (ZLAB.US) rises more than 14%

According to the Securities Times app, on Thursday, Chinese pharmaceutical stocks rebounded after falling in the previous day. As of the time of writing, Zai Ding Medicine (ZLAB.US) rose by over 14% to $32.5, BeiGene (ONC.US) rose by over 6% to $333.25, Hutchison Medicine (HCM.US) rose by over 3.5% to $16.265, and Legend Biotech (LEGN.US) rose by over 2% to $34.14. On the news front, Goldman Sachs released a report stating that the U.S. government under President Trump is discussing restricting Chinese drugs and drafting an executive order (EO) aimed at limiting the entry of Chinese innovative drugs into the U.S. market through multiple measures. In terms of potential short-term stock price risks, it is expected that the impact on companies such as BeiGene and Legend Biotech, which have a global presence, will be limited as these companies have already established a solid foundation in markets like the U.S. and the market has low expectations for additional trading.